

19. Use of the compound according to any one of claims 1 to 15 or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of a BTK- and/or JAK3-mediated disease.

5 20. The use according to claim 19, wherein the disease is selected from the group consisting of an autoimmune disease, an inflammatory disease, a heteroimmune condition or disease, a thromboembolic disease, and a cancer.

10 21. The use according to claim 19, wherein the disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile arthritis, chronic obstructive pulmonary diseases, multiple sclerosis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

15 22. The use according to claim 21, wherein the cancer is selected from the group consisting of B-cell chronic lymphocytic leukemia, acute lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, acute myelogenous leukemia, diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, and small lymphocytic lymphoma.

20 23. A method of inhibiting BTK and/or JAK3 activities in a biological system comprising bringing the biological system into contact with the compound according to any one of claims 1 to 15, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof, or with the pharmaceutical composition according to claim 16 or 17.

25 24. The method according to claim 23, wherein the biological system is an enzyme, a cell or a mammal.

30 25. A method of preventing or treating a BTK- and/or JAK3-mediated disease comprising administering to a subject in need thereof a therapeutically effective amount of the compound according to any one of claims 1 to 15, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof, or of the pharmaceutical composition according to claim 16 or 17.

26. The method according to claim 25, wherein the disease is selected from the group

consisting of an autoimmune disease, an inflammatory disease, a heteroimmune condition or disease, a thromboembolic disease, or a cancer.

- 5 27. Use of the compound according to any one of claims 1 to 15, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof in combination with one or more active agents selected from the group consisting of an immunosuppressant, a corticosteroid, a nonsteroidal anti-inflammatory drug, a Cox-2 specific inhibitor, a TNF- α binding protein, an interferon and an interleukin in the manufacture of a medicament for treating a BTK- and/or JAK3-mediated disease.

19. Use of the compound according to any one of claims 1 to 15 or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the prevention or treatment of a BTK- and/or JAK3-mediated disease.

5 20. The use according to claim 19, wherein the disease is selected from the group consisting of an autoimmune disease, an inflammatory disease, a heteroimmune condition or disease, a thromboembolic disease, and a cancer.

10 21. The use according to claim 19, wherein the disease is selected from the group consisting of rheumatoid arthritis, osteoarthritis, juvenile arthritis, chronic obstructive pulmonary diseases, multiple sclerosis, systemic lupus erythematosus, psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis, and irritable bowel syndrome.

15 22. The use according to claim 21, wherein the cancer is selected from the group consisting of B-cell chronic lymphocytic leukemia, acute lymphocytic leukemia, non-Hodgkin's lymphoma, Hodgkin's lymphoma, acute myelogenous leukemia, diffuse large B-cell lymphoma, multiple myeloma, mantle cell lymphoma, and small lymphocytic lymphoma.

20 23. A method of inhibiting BTK and/or JAK3 activities in a biological system comprising bringing the biological system into contact with the compound according to any one of claims 1 to 15, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof, or with the pharmaceutical composition according to claim 16 or 17, wherein the biological system is an enzyme or a cell.

25 24. Use of the compound according to any one of claims 1 to 15, or a stereoisomer, a tautomer, a solvate, or a pharmaceutically acceptable salt thereof, in combination with one or more active agents selected from the group consisting of an immunosuppressant, a corticosteroid, a nonsteroidal anti-inflammatory drug, a Cox-2 specific inhibitor, a TNF- α binding protein, an interferon and an interleukin in the manufacture of a medicament for treating a BTK- and/or
30 JAK3- mediated disease.